Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MGLycan

Financiado

Cerrado

Targeting hMGL GalNAc interactions to reverse immune suppression in cancer

The appearance of aberrant glycans on the tumor cell surface is one of the emerging hallmarks of cancer. Tumor growth is accompanied by tumor evasion of the immune system which limits the efficacy of cancer vaccines. However, and... ver más

08/10/2021

ASOC CENTRO DE INV...

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

ASOC CENTRO DE INVESTIGACION COOP EN BIO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 3-4 | 6M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-10-08

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ASOC CENTRO DE INVESTIGACION...

172.93K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IMMUNOSHAPE Development of Selective Carbohydrate Immunomodulators Targe... 4M€ Cerrado

InnoTACA Innovation Associate for highly specific Tumour Associated C... 100K€ Cerrado

SweetAim Selective glycoimmuno targeting for cancer therapy 1M€ Cerrado

Crosstag Unravelling cross presentation pathways using a chemical bio... 2M€ Cerrado

ARGONAUT ARGONAUT from the synthesis of gAnglioside tumouR antiGens... 207K€ Cerrado

SweetCancerTest Diagnostics of aberrant cancer glycosylation signatures Cerrado

Duración del proyecto: 29 meses Fecha Inicio: 2019-04-11
Fecha Fin: 2021-10-08

Líder del proyecto

ASOC CENTRO DE INVESTIGACION COOP EN BIO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 3-4 | 6M€

Presupuesto del proyecto 173K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The appearance of aberrant glycans on the tumor cell surface is one of the emerging hallmarks of cancer. Tumor growth is accompanied by tumor evasion of the immune system which limits the efficacy of cancer vaccines. However, and despite the fact that aberrant tumor glycosylation alters how the immune system perceives the tumor and, can also induce immunosuppressive signaling through glycan-binding receptors, the role of tumor glycosylation in immune evasion has mostly been overlooked. It is clear that new strategies to avoid the immune escape mechanisms generated by tumor cells are required. The interaction between the immune system and Tumor-Associated Carbohydrates Antigens (TACAs) is facilitated by a diverse set of carbohydrate-binding receptors, as the C-type lectin receptors (CLRs) which mediate specific interactions with TACAs controlling many features of the immune response. The immune escape mechanisms generated by truncated O-glycans, such as Tn antigen (αGalNAc-Ser/Thr) are still poorly understood. Human macrophage galactose-type lectin (hMGL) is a CLR that recognizes terminal GalNAc moieties, and is, therefore, a prime receptor for the aberrant O-glycans in cancer. MGL is upregulated in tolerogenic and immature dendritic cells (DCs) and macrophages playing an important role in immunosuppression. It interacts with effector T-cells, resulting in reduced proliferation, cytokine secretion and induction of T-cell apoptosis. In this project, we propose the design and synthesis of multivalent MGL ligands mimetics with an improved affinity toward this receptor, that will serve as selective inhibitors to reverse GalNAc-mediated immune suppression for cancer immunotherapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores